Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers

Clinical Therapeutics

Volumn 32, Issue 12, 2010, Pages 2106-2115

  Belotto, Karisa Cristina Rodrigues ^a   Raposo, Nádia Rezende Barbosa ^a,b   Ferreira, Aline Siqueira ^a   Gattaz, Wagner Farid ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Bioavailability; Bioequivalence; Human; LC MS MS; Pharmacokinetic; Risperidone

Indexed keywords

PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INSOMNIA; LOW BACK PAIN; MALE; NAUSEA; NORMAL HUMAN; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BRAZIL; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY;

EID: 78649583418     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.11.006     Document Type: Article

References (29)

1. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N EnglJ Med. 2002, 347:314-321. Research Units on Pediatric Psychopharmacology Autism Network.
2. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005, 162:1142-1148.
3. Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. DrugMetab Dispos. 1993, 21:1134-1141.
4. Huang ML, Van Peer R, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993, 54:257-268.
5. Aman GM, Vinks AA, Remmerie B, et al. Plasma pharmacokinetic characteristics of risperidone and their relation- ship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther. 2007, 29:1476-1486.
6. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1988, 247:661-670.
7. Sattanathan P, Babu JM, Vyas K, et al. Structural studies of impurities of risperidone by hyphenated techniques. J Pharm Biomed Anal. 2006, 40:598-604.
8. Llerena A, Berecz R, Dorado P, et al. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: Application to the evaluation of CYP2D6 drug interactions. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 783:213-219.
9. Remmerie BM, Sips LL, de Vries R, et al. Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 783:461-472.
10. Avenoso A, Facciolà G, Salemi M, Spina E Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2000, 746:173-181.
11. Snoeck E, Van Peer A, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl). 1995, 122:223-229.
12. Scordo MG, Spina E, Facciolà G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999, 147:300-305.
13. Diário Oficial da República Federativa do Brasil July 20, 1993, 8269-8281. no. 116, seção 1.
14. Miranda ES, Pinto CD, Reis AL, et al. Disponibilidade no setor público e preços no setor privado: Um perfil de medicamentos genéricos em diferentes regiões do Brasil. Cad Saude Publica. 2009, 25:2147-2158.
15. Resolução RE n.1170. Agência Nacional de Vigilância Sanitária-Guia para provas de biodisponibilidade e bioequivalência de medicamentos 2006, ANVISA, Diário Oficial da União, Brasília.
16. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations 2002, US Dept of Health and Human Services, Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed January 28, 2008. http://www.fda.gov/cder/guidance/4964dft.htm.
17. Faul F, Erdfelder E, Lang AG, Buchner A G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007, 39:175-191.
18. World Medical Asso- ciation-Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 59th WMA General Assembly October 2008, World Medical Association (WMA), Seoul, Korea, Accessed January 16, 2009. http://www.wma.net/en/30publications/10policies/b3/index.html.
19. Guideline for Good Clinical Practice. ICH topic E 6 (R1) European Agency for the Evaluation of Medicinal Products (EMEA), International Conference on HarmonisationInternational Conference on Harmonisation, Accessed March 16, 2009. http://www.ema.europa.eu/pdfs/human/ich/013595en.pdf.
20. Gorina AB A clínica e o laboratório 1996, 159. MEDSI, Rio de Janeiro, Brazil. 16th ed.
21. Gorina AB A clínica e o laboratório 1996, 527. MEDSI, Rio de Janeiro, Brazil. 16th ed.
22. Leite LA, Silva NM, Miranda MS Comparação entre a contagem de plaquetas pelos métodos manual e automatizado 2007, Newslab, ão Paulo, Brazil. 81st ed.
23. Lima AO, Soares JB, Greco JB, et al. Métodos de laboratório aplicados a clinica. Técnica e Interpretação 1992, 2-32. Guanabara Koogan SA, Rio de Janeiro, Brazil. 7th ed.
24. Lima AO, Soares JB, Greco JB, et al. Métodos de laboratório aplicados a clinica. Técnica e Interpretação 1992, 21-93. Guanabara Koogan SA, Rio de Janeiro, Brazil. 7th ed.
25. Vallada EP Manual de técnicas hematológicas 1996, 193. Atheneu, São Paulo, Brazil.
26. Vallada EP Manual de técnicas hematológicas 1996, 239. Atheneu, São Paulo, Brazil.
27. Chow S-C, Liu J-P Design and Analysis of Bioavailability and Bioequivalence Studies 2000, Marcel Dekker, New York, NY. 2nd ed.
28. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish inter-changeability 2004, World Health Organization (WHO), World Health Organization, Geneva, Switzerland, 39th WHO Expert Committee on Specifications for Pharmaceutical Preparations., Accessed December 1, 2009. http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf.
29. Canovas M, Delgadillo J, Torres F, et al. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2009, 47:124-131.